4//SEC Filing
YAO TONY DUNG LING 4
Accession 0001209191-19-021849
CIK 0001357874other
Filed
Mar 28, 8:00 PM ET
Accepted
Mar 29, 6:37 PM ET
Size
6.6 KB
Accession
0001209191-19-021849
Insider Transaction Report
Form 4
YAO TONY DUNG LING
Director
Transactions
- Other
Convertible Promissory Note
2019-03-27$500000.00/sh(indirect: By ArrowMark Life Science Fund, LP)Exercise: $13.60→ Common Stock (36,946 underlying)
Footnotes (2)
- [F1]On March 1, 2019, ArrowMark Life Science Fund, LP (the "ArrowMark Fund") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.
- [F2]The 2019 Note is held of record by the ArrowMark Fund. ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein.
Documents
Issuer
PRECISION BIOSCIENCES INC
CIK 0001357874
Entity typeother
Related Parties
1- filerCIK 0001771680
Filing Metadata
- Form type
- 4
- Filed
- Mar 28, 8:00 PM ET
- Accepted
- Mar 29, 6:37 PM ET
- Size
- 6.6 KB